AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39394183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 39394576 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe-falling training program
Number of subjects: 8
Study 39394603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic lighting condition with increased brightness in the morning
Number of subjects: 70
Study 39394603 — intervention group
Group type: COMPARATOR
Intervention: Static lighting condition with fixed brightness and color
Number of subjects: 70
Study 39394603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic lighting condition with increased morning brightness after cross-over
Number of subjects: 70
Study 39394763 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-rich PRP (LR-PRP)
Number of subjects: 132
Study 39394763 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte-poor PRP (LP-PRP)
Number of subjects: 132
Study 39394845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepidermal nerve fiber density (IENFD)
Number of subjects: 140
Study 39394845 — intervention group
Group type: COMPARATOR
Intervention: Confocal corneal microscopy (CCM)
Number of subjects: 140
Study 39394845 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Screening Instrument questionnaire (MNSIq)
Number of subjects: 140
Study 39395074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating quantitative flow ratio derived pullback pressure gradient (QFR-PPG) and four conventional parameters
Number of subjects: 421
Study 39395139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care services (medication reconciliation, medication review, patient education)
Number of subjects: 193
Study 39395230 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccination (specific dosage and duration not mentioned)
Number of subjects: 364
Study 39395230 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccination
Number of subjects: 364
Study 39395231 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v 10 mg administered once every 3 weeks (Q3W) or once weekly (QW) for 4 weeks then once every 2 weeks (Q2W) with corresponding atezolizumab regimens.
Number of subjects: 48
Study 39395231 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v plus atezolizumab in PD-L1 positive patients.
Number of subjects: 48
Study 39395231 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v plus atezolizumab in PD-L1 negative patients.
Number of subjects: 48
Study 39395231 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v plus atezolizumab.
Number of subjects: 48
Study 39395266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib monotherapy
Number of subjects: 520
Study 39395266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib combined with chemotherapy and/or anti-PD-1 antibodies
Number of subjects: 520
Study 39395266 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 520
Study 39395411 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 plus chemotherapy (combo)
Number of subjects: 349
Study 39395424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir long-acting injectable
Number of subjects: 984
Study 39395424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PrEP
Number of subjects: 984
Study 39395424 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP
Number of subjects: 984
Study 39395424 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (oral PrEP and PEP)
Number of subjects: 984
Study 39395424 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 984
Study 39395532 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrable, patient-facing family history software platform based on SMART on FHIR standard
Number of subjects: 0
Study 39395532 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrable, patient-facing family history software platform
Number of subjects: 0
Study 39395531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive postpartum BP control - nifedipine initiation at BP ≥140/90 mmHg to maintain BP <140/90 mmHg
Number of subjects: 60
Study 39395531 — intervention group
Group type: COMPARATOR
Intervention: Less intensive postpartum BP control - nifedipine initiation at BP ≥150/100 mmHg to maintain BP <150/100 mmHg
Number of subjects: 60
Study 39395534 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Symptom Monitoring (ASM)
Number of subjects: 540
Study 39395534 — intervention group
Group type: COMPARATOR
Intervention: Patient education without Active Symptom Monitoring (ASM)
Number of subjects: 540
Study 39395566 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Exclusion (LAAE) with AtriClip during cardiac surgery
Number of subjects: 6500
Study 39395566 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6500
Study 39395655 — intervention group
Group type: EXPERIMENTAL
Intervention: Garetosmab (anti-activin A antibody)
Number of subjects: 0
Study 39395655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39395753 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent recombinant influenza vaccine (RIV4)
Number of subjects: 415
Study 39395753 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose inactivated influenza vaccine (IIV4)
Number of subjects: 415
Study 39395826 — intervention group
Group type: EXPERIMENTAL
Intervention: henagliflozin combined with CSII
Number of subjects: 200
Study 39395961 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in patients with high remnant cholesterol (HRC)
Number of subjects: 1106
Study 39395961 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in patients with normal remnant cholesterol (NRC)
Number of subjects: 1106
Study 39395961 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in patients with high triglyceride (HTG)
Number of subjects: 1106
Study 39395961 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in patients with normal triglyceride (NTG)
Number of subjects: 1106
Study 39395964 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA)
Number of subjects: 108
Study 39395964 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular acupressure (SAA)
Number of subjects: 108
Study 39395964 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosage reduction
Number of subjects: 108
Study 39396187 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Visual Function Classification System (VFCS)
Number of subjects: 2
Study 39396529 — intervention group
Group type: EXPERIMENTAL
Intervention: Denifanstat 50 mg once per day for 52 weeks
Number of subjects: 168
Study 39396529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 39396632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 20
Study 39396702 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DHA supplementation
Number of subjects: 132
Study 39396702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 39396714 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleprehabilitation program (personalized multimodal teleprehabilitation)
Number of subjects: 394
Study 39396714 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 394
Study 39396714 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleprehabilitation program
Number of subjects: 394
Study 39396760 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete protein (lean beef)
Number of subjects: 9
Study 39396760 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary protein sources (navy/black beans and whole wheat bread)
Number of subjects: 9
Study 39396760 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete protein meal (black beans or whole wheat bread at 1 meal)
Number of subjects: 9
Study 39396760 — intervention group
Group type: COMPARATOR
Intervention: Low-protein control meal (5 g protein)
Number of subjects: 9
Study 39396938 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 lockdown group
Number of subjects: 263
Study 39396938 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately following the initial lockdown
Number of subjects: 263
Study 39396938 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID-19 lockdown group
Number of subjects: 263
Study 39396960 — intervention group
Group type: EXPERIMENTAL
Intervention: High body fat variation rate
Number of subjects: 4609
Study 39396960 — intervention group
Group type: EXPERIMENTAL
Intervention: High body fat variation rate in participants with BMI > 30
Number of subjects: 4609
Study 39396960 — intervention group
Group type: COMPARATOR
Intervention: Low body fat variation rate
Number of subjects: 4609
Study 39396984 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-based preventive intervention with feedback and lifestyle counselling (n=15)
Number of subjects: 27
Study 39396984 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving feedback only from standard medical examination (n=12)
Number of subjects: 27
Study 39396987 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus block (anesthetic and steroid combination injected into the celiac plexus)
Number of subjects: 0
Study 39396987 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (saline injected into the gastric lumen)
Number of subjects: 0
Study 39396987 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus block
Number of subjects: 0
Study 39396987 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 0
Study 39396991 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy (iCBT) with planned feedback
Number of subjects: 168
Study 39396991 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy (iCBT) with on-demand feedback
Number of subjects: 168
Study 39396991 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 168
Study 39397156 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive mother's own milk (MOM), N=55 (35%)
Number of subjects: 158
Study 39397156 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor human milk (DHM) ± MOM, N=52 (33%)
Number of subjects: 158
Study 39397156 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula ± MOM, N=51 (32%)
Number of subjects: 158
Study 39397156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative intake >150 ml/kg MOM ± DHM within 7-10 days PNA
Number of subjects: 158
Study 39397156 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intestinal permeability (IP)
Number of subjects: 158
Study 39397221 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c)
Number of subjects: 247
Study 39397266 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PDD-TURBT and omitting Re-TURBT
Number of subjects: 327
Study 39397266 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) comprising primary white-light (WL) TURBT followed by second WL Re-TURBT
Number of subjects: 327
Study 39397266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 327
Study 39397363 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 127
Study 39397363 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Management (BMT)
Number of subjects: 127
Study 39397784 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-2-CoV_Beta vaccine (orf virus-based multi-antigen COVID-19 vaccine)
Number of subjects: 0
Study 39398317 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IgE therapy (omalizumab)
Number of subjects: 578
Study 39398317 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-5/5R therapy
Number of subjects: 578
Study 39398317 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-4R therapy
Number of subjects: 578
Study 39398329 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved adherence to vitamin D and calcium supplementation
Number of subjects: 40
Study 39398493 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative stereotactic radiotherapy (SRT)
Number of subjects: 61
Study 39398493 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKI + SRT
Number of subjects: 61
Study 39398493 — intervention group
Group type: COMPARATOR
Intervention: EGFR-TKI
Number of subjects: 61
Study 39399024 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) counseling sessions
Number of subjects: 44
Study 39399034 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased exposure to mother's speech (T-group: n=21) - 10-minute audio recordings of mothers reading a children's story two times/hour between 10pm-6am, increasing speech exposure by 2.67 hours/day
Number of subjects: 46
Study 39399034 — intervention group
Group type: COMPARATOR
Intervention: Routine exposure to mother's speech (C-group: n=25)
Number of subjects: 46
Study 39399572 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualifying prodrome events identified by participants
Number of subjects: 920
Study 39399572 — intervention group
Group type: EXPERIMENTAL
Intervention: Common prodromal symptoms
Number of subjects: 920
Study 39399678 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral HIV preventive intervention for substance using cis and trans gay and bisexual men who have sex with men (GBMSM)
Number of subjects: 68
Study 39399770 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative subacromial injection of bupivacaine and epinephrine
Number of subjects: 60
Study 39399770 — intervention group
Group type: COMPARATOR
Intervention: Preoperative subacromial injection of bupivacaine
Number of subjects: 60
Study 39399879 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-46000 once monthly (q1m)
Number of subjects: 0
Study 39399879 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-46000 once every 2 months (q2m)
Number of subjects: 0
Study 39399879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39400005 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive remote monitoring (RM) including a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias
Number of subjects: 652
Study 39400005 — intervention group
Group type: COMPARATOR
Intervention: Standard daily remote monitoring (control group)
Number of subjects: 652
Study 39400005 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive remote monitoring (RM)
Number of subjects: 652
Study 39400109 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL6) inhibitors
Number of subjects: 0
Study 39400109 — intervention group
Group type: EXPERIMENTAL
Intervention: Janus kinase (JAK) inhibitors (upadacitinib at 15 mg daily)
Number of subjects: 0
Study 39400109 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (an IL17 inhibitor)
Number of subjects: 0
Study 39400109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 39400109 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study 39400233 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 202
Study 39400233 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional liver model
Number of subjects: 202
Study 39400265 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formulation, details on dosage and duration not available
Number of subjects: 0
Study 39400265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39400386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 39400388 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA combined with decitabine (DEC)
Number of subjects: 0
Study 39400388 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC + ATRA
Number of subjects: 0
Study 39400529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cention N (CN) restorations
Number of subjects: 25
Study 39400529 — intervention group
Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RM-GIC) restorations
Number of subjects: 25
Study 39400529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cention N + adhesive system
Number of subjects: 25
Study 39400529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cention N + retentive groove
Number of subjects: 25
Study 39400535 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored 3- to 5-day exercise programme (n=64)
Number of subjects: 130
Study 39400535 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care (control, n=66)
Number of subjects: 130
Study 39400653 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy group (inhaled Lavender essential oil)
Number of subjects: 100
Study 39400653 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (distilled water)
Number of subjects: 100
Study 39400721 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) implemented from July to November.
Number of subjects: 166
Study 39400721 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no SMC).
Number of subjects: 166
Study 39400778 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval group using Bot Fit
Number of subjects: 45
Study 39400778 — intervention group
Group type: EXPERIMENTAL
Intervention: Power group using Bot Fit
Number of subjects: 45
Study 39400778 — intervention group
Group type: COMPARATOR
Intervention: Control group exercising without Bot Fit
Number of subjects: 45
Study 39401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Free SDC (Summer Day Camp) every weekday for 8 to 10 weeks
Number of subjects: 422
Study 39401051 — intervention group
Group type: COMPARATOR
Intervention: Summer as usual (control)
Number of subjects: 422
Study 39401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Free SDC (Summer Day Camp) attendance
Number of subjects: 422
Study 39401051 — intervention group
Group type: COMPARATOR
Intervention: No attendance to summer programming
Number of subjects: 422
Study 39401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Every weekday attendance to summer programming
Number of subjects: 422
Study 39401188 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 sets of 4 repetitions (33% intensity of effort) with 45 s of inter-set recovery
Number of subjects: 60
Study 39401188 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 sets of 6 repetitions (50% intensity of effort) with 72 s of inter-set recovery
Number of subjects: 60
Study 39401188 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 sets of 9 repetitions (75% intensity of effort) with 120 s of inter-set recovery
Number of subjects: 60
Study 39401188 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 60
Study 39401208 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP target of 65 mmHg
Number of subjects: 0
Study 39401208 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP target of 75 mmHg
Number of subjects: 0
Study 39401208 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP target of 85 mmHg
Number of subjects: 0
Study 39401208 — intervention group
Group type: COMPARATOR
Intervention: Recommended MAP target of 65 mmHg
Number of subjects: 0
Study 39401332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal transplantation of ProtheraCytes
Number of subjects: 0
Study 39401503 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-104IAR (25 mg intra-articular injection)
Number of subjects: 318
Study 39401503 — intervention group
Group type: COMPARATOR
Intervention: Vehicle Control
Number of subjects: 318
Study 39401503 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-104IAR
Number of subjects: 318
Study 39401504 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulphate 12.5 mg for 6-23 months; 30.0 mg for 24 months and older)
Number of subjects: 200
Study 39401504 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulphate)
Number of subjects: 200
Study 39401504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 39401872 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 521
Study 39401872 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 521
Study 39402005 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal-artery stenting
Number of subjects: 906
Study 39402005 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 906
Study 39402027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS)
Number of subjects: 26
Study 39402027 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS)
Number of subjects: 26
Study 39402032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp treatment
Number of subjects: 69
Study 39402039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyroglutamated apelin-13
Number of subjects: 24
Study 39402039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 39402448 — intervention group
Group type: EXPERIMENTAL
Intervention: IV difelikefalin (3.0 mcg/kg) in NDD subjects with mild renal impairment
Number of subjects: 55
Study 39402448 — intervention group
Group type: EXPERIMENTAL
Intervention: IV difelikefalin (3.0 mcg/kg) in NDD subjects with moderate or severe renal impairment
Number of subjects: 55
Study 39402448 — intervention group
Group type: COMPARATOR
Intervention: IV difelikefalin (0.5, 1.0, or 2.5 mcg/kg) in ESRD subjects undergoing HD
Number of subjects: 55
Study 39402448 — intervention group
Group type: EXPERIMENTAL
Intervention: IV difelikefalin (3 times per week following dialysis) in ESRD subjects
Number of subjects: 55
Study 39402517 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+ therapy
Number of subjects: 19
Study 39402559 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional tissue clips (CG-TAD)
Number of subjects: 126
Study 39402559 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSI lymph node marking (CN-LNM)
Number of subjects: 126
Study 39402559 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritumoral CNSI mapping (PCN-MAP)
Number of subjects: 126